fig2

Longitudinal biomarker evaluation in Fabry disease patients receiving lentivirus-mediated gene therapy

Figure 2. Urine and plasma specimen collection time points according to the types of treatment for 5 Fabry patients who received gene therapy.

Rare Disease and Orphan Drugs Journal
ISSN 2771-2893 (Online)
Follow Us

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/